Autotaxin/lysophosphatidic acid axis promotes periodontitis by modulating macrophage
By Enyan Liu, Jiacheng Ding, Yiting Jiang, Yining Zhou, Lina Xu, Zhiyan He, Wei Zhou, Zhongchen Song
Originally at onlinelibrary.wiley.com
Summary & scoring by The Bell Brief (Dr. Jennifer Bell) using the Drill-Down Protocol (Drill-Down Score) — not the original publisher.
Why it matters for dental
Periodontitis patients and periodontists may gain a new pharmacologic target: the ATX/LPA pathway that drives both alveolar bone loss and inflammation. Blocking ATX reduced osteoclast activity in a mouse model, suggesting a potential future adjunct to mechanical therapy for moderate-to-severe cases.
Key points
- Clinical samples from periodontitis patients showed higher ATX/LPA expression than healthy controls, and expression levels rose with disease severity.
- Macrophage Atx knockout mice developed milder periodontal inflammation and less alveolar bone resorption than wild-type littermates.
- Bone-marrow-derived macrophages lacking Atx produced fewer osteoclasts and lower inflammatory mediators after P. gingivalis LPS stimulation.
- Systemic administration of the ATX inhibitor PF8380 reduced alveolar bone loss in periodontitis mice and altered macrophage osteoclast differentiation.
Who should care
Read the original on Journal of Clinical Periodontology
Full reporting and any paywall content live on onlinelibrary.wiley.com. We summarize and score; we do not republish.
Related
- ·Regulatory
Is fluoride still safe for kids? A dentist breaks down what the research actually shows
- ·Research
Fanconi anemia: matrix remodeling and oral carcinogenesis
- ·Research
Inflammasome-related transcriptomic profiles in periodontitis
- ·Research
Clinical efficacy of platelet-rich fibrin therapy during oral surgical interventions